Aardvark Therapeutics (AARD) Depreciation & Amortization (CF) (2024 - 2026)
Aardvark Therapeutics (AARD) posted Depreciation & Amortization (CF) of $11000.0 for Q1 2026, up 10.0% sequentially from $10000.0 in Q4 2025, and up 120.0% YoY from $5000.0 in Q1 2025.
Aardvark Therapeutics (AARD) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $11000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 120.0% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42000.0 (up 121.05% YoY) and the FY2025 annual result came in at $36000.0, up 125.0% from the prior year.
- Depreciation & Amortization (CF) advanced to $11000.0 in Q1 2026 per AARD's latest filing, from $10000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $11000.0 in Q2 2025 and troughed at -$2000.0 in Q2 2024.
- A 3-year average of $7000.0 and a median of $8000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 650.0% in 2025, down 25.0% in 2025.
- Over 3 years, Depreciation & Amortization (CF) stood at $8000.0 in 2024, then climbed by 25.0% to $10000.0 in 2025, then climbed by 10.0% to $11000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $11000.0, $10000.0, and $10000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11,000.00 |
| Jun 30, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |